EWTX
insider transactionsEdgewise Therapeutics, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 365d
-237.1K
0 buy · 237.1K sell
Net value · 365d
-$7.6M
$0 in · $7.6M out
Sentiment · 365d
Net selling
0% buying · 100% selling
Open-market trades · 365d
11
0 buy · 237.1K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Grant·A
Director
$0
16.4K sh
Own New
-
Grant·A
Director
$0
8.2K sh
Own New
-
Grant·A
Director
$0
5.6K sh
Own New
-
Grant·A
Director
$0
16.4K sh
Own New
-
Grant·A
Director
$0
16.4K sh
Own New
-
Grant·A
Director, 10% Owner
$0
16.4K sh
Own New
-
Exercise·M
$0
50.0K sh
Own +200%
-
Sell·S
$1.9M
50.0K sh · $38.57
Own -92%
-
Exercise·M
$354.0K
50.0K sh · $7.08
Own +1145%
-
Sell·S
$163.7K
5.2K sh · $31.29
Own -54%
-
Exercise·M
CMO · 10b5-1
$0
28.7K sh
Own +30%
-
Sell·S
CMO · 10b5-1
$926.1K
28.7K sh · $32.31
Own -75%
-
Exercise·M
CMO · 10b5-1
$202.9K
28.7K sh · $7.08
Own +299%
-
Grant·A
Director
$0
339 sh
Own +1%
-
Exercise·M
CMO · 10b5-1
$0
21.3K sh
Own +16%
-
Sell·S
CMO · 10b5-1
$685.3K
21.3K sh · $32.12
Own -69%
-
Exercise·M
CMO · 10b5-1
$151.1K
21.3K sh · $7.08
Own +222%
-
Sell·S
CMO · 10b5-1
$208.6K
6.7K sh · $30.98
Own -41%
-
Sell·S
CMO · 10b5-1
$298.1K
9.6K sh · $30.98
Own -37%
-
Exercise·M
Director · 10b5-1
$0
13.7K sh
Own New
-
Exercise·M
Director · 10b5-1
$0
17.2K sh
Own New
-
Exercise·M
Director · 10b5-1
$0
7.6K sh
Own New
-
Exercise·M
Director · 10b5-1
$0
66.5K sh
Own New
-
Exercise·M
Director · 10b5-1
$0
10.5K sh
Own New
-
Sell·S
Director · 10b5-1
$2.0M
66.5K sh · $29.44
Own -77%
-
Sell·S
Director · 10b5-1
$308.0K
10.5K sh · $29.44
Own -11%
-
Sell·S
Director · 10b5-1
$223.9K
7.6K sh · $29.44
Own -7%
-
Sell·S
Director · 10b5-1
$507.4K
17.2K sh · $29.44
Own -14%
-
Sell·S
Director · 10b5-1
$403.0K
13.7K sh · $29.44
Own -10%
-
Exercise·M
Director · 10b5-1
$5.4K
7.6K sh · $0.71
Own +6%
-
Exercise·M
Director · 10b5-1
$128.3K
66.5K sh · $1.93
Own +109%
-
Exercise·M
Director · 10b5-1
$20.2K
10.5K sh · $1.93
Own +21%
-
Exercise·M
Director · 10b5-1
$11.0K
17.2K sh · $0.64
Own +51%
-
Exercise·M
Director · 10b5-1
$5.3K
13.7K sh · $0.39
Own +69%
-
Grant·A
Director
$0
473 sh
Own +2%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 5, 2026 | Christopher Nathan Martin | Grant A | 16.4K | $0 |
| Jun 5, 2026 | Badreddin Edris | Grant A | 8.2K | $0 |
| Jun 5, 2026 | Badreddin Edris | Grant A | 5.6K | $0 |
| Jun 5, 2026 | Jonathan C Fox | Grant A | 16.4K | $0 |
| Jun 5, 2026 | Arlene Morris | Grant A | 16.4K | $0 |
| Jun 5, 2026 | Peter A. Thompson | Grant A | 16.4K | $0 |
| May 5, 2026 | Joanne M. Donovan | Exercise M | 50.0K | $0 |
| May 5, 2026 | Joanne M. Donovan | Sell S | 50.0K | $1.9M |
| May 5, 2026 | Joanne M. Donovan | Exercise M | 50.0K | $354.0K |
| May 4, 2026 | Joanne M. Donovan | Sell S | 5.2K | $163.7K |
| Apr 1, 2026 | Joanne M. Donovan 10b5-1 | Exercise M | 28.7K | $0 |
| Apr 1, 2026 | Joanne M. Donovan 10b5-1 | Sell S | 28.7K | $926.1K |
| Apr 1, 2026 | Joanne M. Donovan 10b5-1 | Exercise M | 28.7K | $202.9K |
| Apr 1, 2026 | Jonathan C Fox | Grant A | 339 | $0 |
| Mar 31, 2026 | Joanne M. Donovan 10b5-1 | Exercise M | 21.3K | $0 |
| Mar 31, 2026 | Joanne M. Donovan 10b5-1 | Sell S | 21.3K | $685.3K |
| Mar 31, 2026 | Joanne M. Donovan 10b5-1 | Exercise M | 21.3K | $151.1K |
| Mar 27, 2026 | Joanne M. Donovan 10b5-1 | Sell S | 6.7K | $208.6K |
| Mar 27, 2026 | Joanne M. Donovan 10b5-1 | Sell S | 9.6K | $298.1K |
| Jan 21, 2026 | Badreddin Edris 10b5-1 | Exercise M | 13.7K | $0 |
| Jan 21, 2026 | Badreddin Edris 10b5-1 | Exercise M | 17.2K | $0 |
| Jan 21, 2026 | Badreddin Edris 10b5-1 | Exercise M | 7.6K | $0 |
| Jan 21, 2026 | Badreddin Edris 10b5-1 | Exercise M | 66.5K | $0 |
| Jan 21, 2026 | Badreddin Edris 10b5-1 | Exercise M | 10.5K | $0 |
| Jan 21, 2026 | Badreddin Edris 10b5-1 | Sell S | 66.5K | $2.0M |
| Jan 21, 2026 | Badreddin Edris 10b5-1 | Sell S | 10.5K | $308.0K |
| Jan 21, 2026 | Badreddin Edris 10b5-1 | Sell S | 7.6K | $223.9K |
| Jan 21, 2026 | Badreddin Edris 10b5-1 | Sell S | 17.2K | $507.4K |
| Jan 21, 2026 | Badreddin Edris 10b5-1 | Sell S | 13.7K | $403.0K |
| Jan 21, 2026 | Badreddin Edris 10b5-1 | Exercise M | 7.6K | $5.4K |
| Jan 21, 2026 | Badreddin Edris 10b5-1 | Exercise M | 66.5K | $128.3K |
| Jan 21, 2026 | Badreddin Edris 10b5-1 | Exercise M | 10.5K | $20.2K |
| Jan 21, 2026 | Badreddin Edris 10b5-1 | Exercise M | 17.2K | $11.0K |
| Jan 21, 2026 | Badreddin Edris 10b5-1 | Exercise M | 13.7K | $5.3K |
| Jan 2, 2026 | Jonathan C Fox | Grant A | 473 | $0 |
About EWTX insider trading
This page tracks insider transactions for Edgewise Therapeutics, Inc. (EWTX) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.